Raymond James analyst Laura Prendergast initiated coverage of Third Harmonic Bio with an Outperform rating and $18 price target. Third Harmonic is well positioned to have a second mover advantage in the incredibly large mast cell disease market, and its broad market opportunity is estimated at roughly $26B, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THRD: